122 related articles for article (PubMed ID: 37664946)
41. Targeted next-generation sequencing for TP53, RAS, BRAF, ALK and NF1 mutations in anaplastic thyroid cancer.
Latteyer S; Tiedje V; König K; Ting S; Heukamp LC; Meder L; Schmid KW; Führer D; Moeller LC
Endocrine; 2016 Dec; 54(3):733-741. PubMed ID: 27696251
[TBL] [Abstract][Full Text] [Related]
42. Genetic Alterations Detected by Targeted Next-generation Sequencing and Their Clinical Implications in Neuroblastoma.
Koh KN; Lee JY; Lim J; Shin J; Kang SH; Suh JK; Kim H; Im HJ; Namgoong JM; Kim DY; Jang SJ; Chun SM
Anticancer Res; 2020 Dec; 40(12):7057-7065. PubMed ID: 33288603
[TBL] [Abstract][Full Text] [Related]
43. Activated Alk triggers prolonged neurogenesis and Ret upregulation providing a therapeutic target in ALK-mutated neuroblastoma.
Cazes A; Lopez-Delisle L; Tsarovina K; Pierre-Eugène C; De Preter K; Peuchmaur M; Nicolas A; Provost C; Louis-Brennetot C; Daveau R; Kumps C; Cascone I; Schleiermacher G; Prignon A; Speleman F; Rohrer H; Delattre O; Janoueix-Lerosey I
Oncotarget; 2014 May; 5(9):2688-702. PubMed ID: 24811913
[TBL] [Abstract][Full Text] [Related]
44. Next generation MUT-MAP, a high-sensitivity high-throughput microfluidics chip-based mutation analysis panel.
Schleifman EB; Tam R; Patel R; Tsan A; Sumiyoshi T; Fu L; Desai R; Schoenbrunner N; Myers TW; Bauer K; Smith E; Raja R
PLoS One; 2014; 9(3):e90761. PubMed ID: 24658394
[TBL] [Abstract][Full Text] [Related]
45. Detection of tumor ALK status in neuroblastoma patients using peripheral blood.
Combaret V; Iacono I; Bellini A; Bréjon S; Bernard V; Marabelle A; Coze C; Pierron G; Lapouble E; Schleiermacher G; Blay JY
Cancer Med; 2015 Apr; 4(4):540-50. PubMed ID: 25653133
[TBL] [Abstract][Full Text] [Related]
46. Clinicopathological features of nonsmall cell lung carcinomas with BRAF mutations.
Kinno T; Tsuta K; Shiraishi K; Mizukami T; Suzuki M; Yoshida A; Suzuki K; Asamura H; Furuta K; Kohno T; Kushima R
Ann Oncol; 2014 Jan; 25(1):138-42. PubMed ID: 24297085
[TBL] [Abstract][Full Text] [Related]
47. Upregulation of MAPK Negative Feedback Regulators and RET in Mutant ALK Neuroblastoma: Implications for Targeted Treatment.
Lambertz I; Kumps C; Claeys S; Lindner S; Beckers A; Janssens E; Carter DR; Cazes A; Cheung BB; De Mariano M; De Bondt A; De Brouwer S; Delattre O; Gibbons J; Janoueix-Lerosey I; Laureys G; Liang C; Marchall GM; Porcu M; Takita J; Trujillo DC; Van Den Wyngaert I; Van Roy N; Van Goethem A; Van Maerken T; Zabrocki P; Cools J; Schulte JH; Vialard J; Speleman F; De Preter K
Clin Cancer Res; 2015 Jul; 21(14):3327-39. PubMed ID: 25805801
[TBL] [Abstract][Full Text] [Related]
48. ALK(R1275Q) perturbs extracellular matrix, enhances cell invasion and leads to the development of neuroblastoma in cooperation with MYCN.
Ueda T; Nakata Y; Yamasaki N; Oda H; Sentani K; Kanai A; Onishi N; Ikeda K; Sera Y; Honda ZI; Tanaka K; Sata M; Ogawa S; Yasui W; Saya H; Takita J; Honda H
Oncogene; 2016 Aug; 35(34):4447-58. PubMed ID: 26829053
[TBL] [Abstract][Full Text] [Related]
49. Low Frequency ALK Hotspots Mutations In Neuroblastoma Tumours Detected By Ultra-deep Sequencing: Implications For ALK Inhibitor Treatment.
Javanmardi N; Fransson S; Djos A; Sjöberg RM; Nilsson S; Truvé K; Kogner P; Martinsson T
Sci Rep; 2019 Feb; 9(1):2199. PubMed ID: 30778092
[TBL] [Abstract][Full Text] [Related]
50. BLM germline and somatic PKMYT1 and AHCY mutations: Genetic variations beyond MYCN and prognosis in neuroblastoma.
Novak EM; Halley NS; Gimenez TM; Rangel-Santos A; Azambuja AM; Brumatti M; Pereira PL; Vince CS; Giorgi RR; Bendit I; Cristofani LM; Odone-Filho V
Med Hypotheses; 2016 Dec; 97():22-25. PubMed ID: 27876123
[TBL] [Abstract][Full Text] [Related]
51. Targeted next generation sequencing of MLH1-deficient, MLH1 promoter hypermethylated, and BRAF/RAS-wild-type colorectal adenocarcinomas is effective in detecting tumors with actionable oncogenic gene fusions.
Vaňková B; Vaněček T; Ptáková N; Hájková V; Dušek M; Michal M; Švajdler P; Daum O; Daumová M; Michal M; Mezencev R; Švajdler M
Genes Chromosomes Cancer; 2020 Oct; 59(10):562-568. PubMed ID: 32427409
[TBL] [Abstract][Full Text] [Related]
52. The R1275Q neuroblastoma mutant and certain ATP-competitive inhibitors stabilize alternative activation loop conformations of anaplastic lymphoma kinase.
Epstein LF; Chen H; Emkey R; Whittington DA
J Biol Chem; 2012 Oct; 287(44):37447-57. PubMed ID: 22932897
[TBL] [Abstract][Full Text] [Related]
53. External Validation of
Kim SW; DO SI; Na K
Anticancer Res; 2021 Sep; 41(9):4609-4617. PubMed ID: 34475089
[TBL] [Abstract][Full Text] [Related]
54. ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features.
Pan Y; Zhang Y; Li Y; Hu H; Wang L; Li H; Wang R; Ye T; Luo X; Zhang Y; Li B; Cai D; Shen L; Sun Y; Chen H
Lung Cancer; 2014 May; 84(2):121-6. PubMed ID: 24629636
[TBL] [Abstract][Full Text] [Related]
55. Next Generation Sequencing Analysis and its Benefit for Targeted Therapy of Lung Adenocarcinoma.
Kulda V; Polivka J; Svaton M; Vanecek T; Buresova M; Houfkova K; Bagheri MS; Knizkova T; Vankova B; Windrichova J; Macan P; Babuska V; Pesta M
Cancer Genomics Proteomics; 2023; 20(4):404-411. PubMed ID: 37400146
[TBL] [Abstract][Full Text] [Related]
56. Lung adenocarcinoma harboring complex EML4-ALK fusion and BRAF V600E co-mutation responded to alectinib.
Guo W; Liang J; Zhang D; Huang X; Lv Y
Medicine (Baltimore); 2022 Oct; 101(40):e30913. PubMed ID: 36221356
[TBL] [Abstract][Full Text] [Related]
57. [Ceritinib in the treatment of an adult patient with advanced neuroblastoma positive to the somatic activating mutation of ALK F1174L.].
Soto Parra HJ; Noto L; Aiello MM
Recenti Prog Med; 2020 Dec; 111(12):58e-62e. PubMed ID: 33362184
[TBL] [Abstract][Full Text] [Related]
58. Potential Unreliability of Uncommon ALK, ROS1, and RET Genomic Breakpoints in Predicting the Efficacy of Targeted Therapy in NSCLC.
Li W; Guo L; Liu Y; Dong L; Yang L; Chen L; Liu K; Shao Y; Ying J
J Thorac Oncol; 2021 Mar; 16(3):404-418. PubMed ID: 33248323
[TBL] [Abstract][Full Text] [Related]
59. Selective therapeutic targeting of the anaplastic lymphoma kinase with liposomal siRNA induces apoptosis and inhibits angiogenesis in neuroblastoma.
Di Paolo D; Ambrogio C; Pastorino F; Brignole C; Martinengo C; Carosio R; Loi M; Pagnan G; Emionite L; Cilli M; Ribatti D; Allen TM; Chiarle R; Ponzoni M; Perri P
Mol Ther; 2011 Dec; 19(12):2201-12. PubMed ID: 21829174
[TBL] [Abstract][Full Text] [Related]
60. A Comparison of Morphologic and Molecular Features of BRAF, ALK, and NTRK1 Fusion Spitzoid Neoplasms.
Amin SM; Haugh AM; Lee CY; Zhang B; Bubley JA; Merkel EA; Verzì AE; Gerami P
Am J Surg Pathol; 2017 Apr; 41(4):491-498. PubMed ID: 27776007
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
